Maria do Sameiro Faria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6253373/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1371-1378.	2.9	11
2	Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 311-317.	0.9	6
3	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. Biomedicines, 2021, 9, 554.	3.2	2
4	MO1023BARDET-BIEDL SYNDROME OR SENIOR-LOKEN SYNDROME? GOING BEYOND THE OBVIOUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
5	MO1022CENTRAL VENOUS CATHETERS FIRST - THE ACHILLES' HEEL IN PEDIATRIC HEMODIALYSIS VASCULAR ACCESS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
6	Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis. Scientific Reports, 2021, 11, 14768.	3.3	13
7	Hemodialysis vascular access in children – A retrospective study in a pediatric dialysis unit. Portuguese Journal of Nephrology & Hypertension, 2021, 35, .	0.1	0
8	Hyperinsulinaemic Hypoglycaemia and Polycystic Kidney Disease – A Rare Case Concerning <i>PMM2</i> Gene Pleiotropy. European Endocrinology, 2020, 16, 66.	1.5	7
9	Management of children with congenital nephrotic syndrome: challenging treatment paradigms. Nephrology Dialysis Transplantation, 2019, 34, 1369-1377.	0.7	32
10	SP666MACHINE LEARNING IN PREDICTION OF VULNERABLE OR RESILIENT END-STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
11	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediators of Inflammation, 2019, 2019, 1-12.	3.0	15
12	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. Renal Failure, 2019, 41, 662-672.	2.1	10
13	SP637INFLAMMATION AND CELL-FREE DNA AS BIOMARKERS FOR THE OUTCOME OF END STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
14	SP543ASSOCIATION OF PTX3, NT-proBNP AND LEFT VENTRICULAR HYPERTROPHY IN PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
15	FP725PENTRAXIN 3 IN END-STAGE RENAL DISEASE: MULTIPLE RISK BIOMARKER AND PREDICTOR OF ALL-CAUSE MORTALITY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
16	FP730EFFECTS OF STATINS THERAPY ON LDL SUBFRACTIONS AND INFLAMMATION, IN END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
17	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	15
18	Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases. Pediatric Nephrology, 2019, 34, 649-655.	1.7	16

#	Article	IF	CITATIONS
19	Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional Dialysis versus Online-Hemodiafiltration. , 2018, , .		Ο
20	SP342HEPCIDIN-25 AND TREATMENT WITH ERYTHROPOIESIS STIMULATING AGENTS ARE INDEPENDENTLY RELATED WITH ERYTHROPOIESIS IN CHRONIC HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i460-i460.	0.7	1
21	Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2–5 and on dialysis. Nephrology Dialysis Transplantation, 2017, 32, 1114-1127.	0.7	51
22	Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2–5 and on dialysis. Nephrology Dialysis Transplantation, 2017, 32, 1098-1113.	0.7	84
23	The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. Revista Portuguesa De Cardiologia, 2017, 36, 709-716.	0.5	11
24	Risk factors for mortality in end-stage kidney disease patients under online-hemodiafiltration: three-year follow-up study. Biomarkers, 2016, 21, 544-550.	1.9	3
25	Tratamento de hiperparatiroidismo secundário grave com paricalcitol em criança de 3 anos em diálise. Revista Portuguesa De Endocrinologia Diabetes E Metabolismo, 2015, 10, 152-155.	0.1	0
26	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. Quality of Life Research, 2015, 24, 1327-1335.	3.1	25
27	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration. , 2015, 6, 17.		6
28	Type of Vascular access and Location in Online Hemodiafiltration and its Association with Patient's Perception of Health-Related Quality of Life. Journal of Vascular Access, 2014, 15, 175-182.	0.9	21
29	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. BioMed Research International, 2014, 2014, 1-9.	1.9	12
30	<scp>BK</scp> virus nephropathy complicated with meningoencephalitis after kidney transplantation. Pediatric Transplantation, 2014, 18, E48-51.	1.0	8
31	Membranoproliferative Glomerulonephritis and X-Linked Agammaglobulinemia: An Uncommon Association. Case Reports in Pediatrics, 2014, 2014, 1-3.	0.4	5
32	TLR4 and TLR9 Polymorphisms Effect on Inflammatory Response in End-Stage Renal Disease Patients. European Journal of Inflammation, 2014, 12, 521-529.	0.5	4
33	Predictive Factors of Graft-Censored Failure in Pediatric Kidney Transplantation. Transplantation Proceedings, 2014, 46, 1723-1726.	0.6	8
34	Haptoglobin 2–2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy. British Journal of Biomedical Science, 2014, 71, 79-81.	1.3	1
35	Infections Following Kidney Transplant in Children: A Single-Center Study. Open Journal of Nephrology, 2014, 04, 117-124.	0.1	2
36	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	1.3	45

Maria do Sameiro Faria

#	Article	IF	CITATIONS
37	Partially Reversible Cardiomyopathy after Renal Transplant Associated with Anti-Troponin I Antibodies. Cardiology, 2013, 126, 173-174.	1.4	8
38	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 2013, 17, n/a-n/a.	0.9	11
39	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 2013, 35, 1392-1398.	2.1	10
40	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. Journal of Vascular Access, 2013, 14, 335-341.	0.9	3
41	Comparison of Bio-Plex measurements with standard techniques. Clinical Chemistry and Laboratory Medicine, 2012, 50, 399-402.	2.3	1
42	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	2.1	4
43	Main Determinants of PON1 Activity in Hemodialysis Patients. American Journal of Nephrology, 2012, 36, 317-323.	3.1	16
44	Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient. Pediatric Nephrology, 2012, 27, 1583-1588.	1.7	13
45	Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis . Scandinavian Journal of Urology and Nephrology, 2012, 46, 461-465.	1.4	1
46	Oxidized lowâ€density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International, 2012, 16, 481-490.	0.9	21
47	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. Hemodialysis International, 2011, 15, 429-431.	0.9	4
48	Impact of Pediatric Kidney Transplantation on Long-Term Professional and Social Outcomes. Transplantation Proceedings, 2011, 43, 120-124.	0.6	22
49	Apoptosis of Peripheral CD4 ⁺ T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. Renal Failure, 2011, 33, 138-143.	2.1	25
50	Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodialysis International, 2010, 14, 295-301.	0.9	26
51	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	1.4	41
52	Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 2009, 71, 233-235.	0.7	0
53	Inflammation, T-Cell Phenotype, and Inflammatory Cytokines in Chronic Kidney Disease Patients Under Hemodialysis and its Relationship to Resistance to Recombinant Human Erythropoietin Therapy. Journal of Clinical Immunology, 2008, 28, 268-275.	3.8	77
54	Changes in Red Blood Cells Membrane Protein Composition during Hemodialysis Procedure. Renal Failure, 2008, 30, 971-975.	2.1	16

#	Article	IF	CITATIONS
55	IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 2008, 41, 134-135.	1.4	4
56	HAEMODIALYSIS FOR CHILDREN UNDER THE AGE OF TWO YEARS. Journal of Renal Care, 2008, 34, 9-13.	1.2	9
57	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	3.1	36
58	Neutrophil Activation and Resistance to Recombinant Human Erythropoietin Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 935-940.	3.1	42
59	Altered Erythrocyte Membrane Protein Composition in Chronic Kidney Disease Stage 5 Patients under Haemodialysis and Recombinant Human Erythropoietin Therapy. Blood Purification, 2008, 26, 267-273.	1.8	18
60	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	1.4	4
61	Band 3 Profile as a Marker of Erythrocyte Changes in Chronic Kidney Disease Patients. The Open Clinical Chemistry Journal, 2008, 1, 57-63.	0.7	11
62	Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 630-633.	3.3	5
63	Apnea/hypopnea index and benzodiazepine use in patients with arterial hypertension and excessive weight. International Journal of Cardiology, 2007, 114, 416-418.	1.7	6
64	Glomerular Filtration Rate and Coronary Artery Disease Burden in Patients with Acute Coronary Syndrome. Clinical Cardiology, 2007, 30, 464-468.	1.8	8
65	Correlation between plasma calcium and coronary artery disease burden in patients with preserved renal function. International Journal of Cardiology, 2005, 98, 363-366.	1.7	8
66	Homocysteine levels in pediatric renal transplant recipients. Transplantation Proceedings, 2003, 35, 1093-1095.	0.6	0
67	Nephropathy associated with heroin abuse in Caucasian patients. Nephrology Dialysis Transplantation, 2003, 18, 2308-2313.	0.7	54
68	Haemolytic uraemic syndrome, cardiomyopathy, cutaneous vasculopathy and antiâ€ p hospholipid activity. Nephrology Dialysis Transplantation, 2000, 15, 1891-1892.	0.7	6
69	IgA Nephropathy and Antiphospholipid Syndrome. Nephron, 1999, 83, 95-96.	1.8	5
70	Assessment of renal dopaminergic system activity during the recovery of renal function in human kidney transplant recipients. Nephrology Dialysis Transplantation, 1997, 12, 2667-2672.	0.7	12
71	Non-Hodgkin lymphoma and glomerulonephritis. What kind of relation?. Nephrology Dialysis Transplantation, 1996, 11, 854-856.	0.7	5
72	Reversible renal failure and SZ alpha1-antitrypsin phenotype. Association with liver disease and ethanol abuse. Nephrology Dialysis Transplantation, 1995, 10, 2340-2342.	0.7	1

#	Article	IF	CITATIONS
73	Hydrocephalus, Hypertension and Renal Failure: Ambulatory Blood Pressure Data. Nephron, 1994, 67, 237-239.	1.8	1
74	Acute ischaemic stroke during ambulatory blood pressure monitoring. Lancet, The, 1992, 339, 1113-1114.	13.7	3